IN2012DN00456A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00456A IN2012DN00456A IN456DEN2012A IN2012DN00456A IN 2012DN00456 A IN2012DN00456 A IN 2012DN00456A IN 456DEN2012 A IN456DEN2012 A IN 456DEN2012A IN 2012DN00456 A IN2012DN00456 A IN 2012DN00456A
- Authority
- IN
- India
- Prior art keywords
- therapeutic
- research
- rapid
- systems
- animal protein
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 abstract 1
- 235000021120 animal protein Nutrition 0.000 abstract 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/145—Clostridium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/502,181 US8129139B2 (en) | 2009-07-13 | 2009-07-13 | Process for obtaining botulinum neurotoxin |
| PCT/US2010/041745 WO2011008713A1 (en) | 2009-07-13 | 2010-07-12 | Process and system for obtaining botulinum neurotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00456A true IN2012DN00456A (enExample) | 2015-05-15 |
Family
ID=42537891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN456DEN2012 IN2012DN00456A (enExample) | 2009-07-13 | 2010-07-12 |
Country Status (18)
| Country | Link |
|---|---|
| US (19) | US8129139B2 (enExample) |
| EP (5) | EP3252070B1 (enExample) |
| JP (6) | JP5887268B2 (enExample) |
| KR (5) | KR101916139B1 (enExample) |
| CN (2) | CN102482332B (enExample) |
| BR (1) | BR112012000784A2 (enExample) |
| CA (1) | CA2767760C (enExample) |
| CY (2) | CY1119519T1 (enExample) |
| DK (2) | DK2454275T3 (enExample) |
| ES (2) | ES2643554T3 (enExample) |
| HU (2) | HUE033888T2 (enExample) |
| IN (1) | IN2012DN00456A (enExample) |
| MX (4) | MX2012000615A (enExample) |
| PL (2) | PL3252070T3 (enExample) |
| PT (2) | PT2454275T (enExample) |
| RU (1) | RU2561459C2 (enExample) |
| SI (2) | SI3252070T1 (enExample) |
| WO (1) | WO2011008713A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| CN1930186A (zh) * | 2005-03-03 | 2007-03-14 | 阿勒根公司 | 为获得梭菌毒素的梭菌细菌培养基及方法 |
| US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP5951490B2 (ja) * | 2009-10-21 | 2016-07-13 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
| KR20110046178A (ko) * | 2009-10-28 | 2011-05-04 | 엘지전자 주식회사 | 이동 단말기 |
| KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| US9605887B2 (en) | 2011-07-29 | 2017-03-28 | Hdt Expeditionary Systems, Inc. | Transportable packaged ice supply system for high temperature environments |
| GB201113544D0 (en) * | 2011-08-05 | 2011-09-21 | Fujifilm Diosynth Biotechnologies Uk Ltd | Purification process |
| WO2014197837A1 (en) * | 2013-06-06 | 2014-12-11 | University Of Florida Research Foundation, Inc. | Materials and methods for producing a biological toxin |
| CN105658662B (zh) * | 2013-07-30 | 2022-05-27 | 莫茨制药有限及两合公司 | 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用 |
| KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| EP3068791B1 (en) * | 2013-11-15 | 2020-07-29 | Novartis AG | Removal of residual cell culture impurities |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| KR101729251B1 (ko) * | 2015-04-28 | 2017-04-21 | 주식회사 대웅 | 보툴리눔 독소의 제조를 위한 배지 조성물 |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| WO2017161345A1 (en) | 2016-03-18 | 2017-09-21 | Biomadison, Inc. | Improved cell based assay |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| KR102463881B1 (ko) | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
| RU2766147C2 (ru) * | 2017-03-22 | 2022-02-08 | Бонти, Инк. | Применение ботулинических нейротоксинов в лечении |
| AU2018258591A1 (en) * | 2017-04-28 | 2019-11-07 | Bonti, Inc. | Botulinum neurotoxins production methods |
| CA3068292A1 (en) * | 2017-06-26 | 2019-01-03 | Bonti, Inc. | Clostridial neurotoxin formulations and use |
| KR102140531B1 (ko) * | 2018-08-07 | 2020-08-04 | (주)휴온스 | Gly-Tβ4의 제조방법 |
| EP3901163A4 (en) | 2018-12-21 | 2022-10-05 | The Research Foundation for Microbial Diseases of Osaka University | PROCESS FOR PRODUCTION OF BOTULINUM TOXIN |
| KR102209159B1 (ko) * | 2019-03-29 | 2021-01-29 | (주)제테마 | 독소의 제조방법 |
| KR102197224B1 (ko) | 2019-03-29 | 2020-12-31 | (주)제테마 | 배지 조성물 |
| KR102516204B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 정제방법 |
| KR102516203B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 제조방법 |
| US10851363B1 (en) * | 2019-05-22 | 2020-12-01 | Boke Zhang | Multilayer nano-cell containing biomolecules |
| KR102287437B1 (ko) * | 2019-08-14 | 2021-08-09 | 주식회사 프로톡스 | 보툴리눔 독소의 제조방법 |
| TW202136286A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商葛德瑪控股公司 | 純化肉毒桿菌毒素的方法 |
| TWI854077B (zh) * | 2019-12-20 | 2024-09-01 | 瑞士商葛德瑪控股公司 | 生產肉毒桿菌毒素的方法 |
| CN114958887B (zh) * | 2021-02-26 | 2024-10-25 | 重庆誉颜制药有限公司 | 一种经修饰的毒素多肽的制备方法 |
| KR102724651B1 (ko) * | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| KR102427362B1 (ko) * | 2021-11-11 | 2022-08-01 | (주)이니바이오 | 보툴리눔 독소 제제의 건조 공정 |
| KR102850152B1 (ko) * | 2022-07-27 | 2025-08-25 | (주)이니바이오 | 감압건조장치 및 이를 이용한 감압건조방법 |
| WO2024102345A1 (en) | 2022-11-07 | 2024-05-16 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
| CH720447A2 (de) * | 2023-01-20 | 2024-07-31 | Abbvie Inc | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a |
| CH720444A2 (de) | 2023-01-20 | 2024-07-31 | Abbvie Inc | Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten |
| WO2025111258A1 (en) * | 2023-11-20 | 2025-05-30 | Abbvie Inc. | Clostridium botulinum neurotoxin serotype a compositions and improved filtration processes |
| DE102025101336A1 (de) | 2024-01-19 | 2025-07-24 | Abbvie Inc. | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401683A (en) | 1981-07-06 | 1983-08-30 | Fmc Corporation | Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin |
| CA2138020C (en) | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
| TW257792B (enExample) * | 1992-10-01 | 1995-09-21 | Lilly Co Eli | |
| FI951701L (fi) | 1992-10-13 | 1995-04-10 | Univ Duke | Menetelmät Alzheimerin taudin tunnistamiseksi |
| US5314822A (en) | 1992-10-15 | 1994-05-24 | Merck & Co., Inc. | Method of clonal growth of Streptococcus pneumoniae |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| US5962637A (en) | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
| WO1996005222A1 (en) | 1994-08-08 | 1996-02-22 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
| US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| DE69627963T2 (de) | 1995-06-06 | 2004-03-04 | Pearce, L. Bruce, Cambridge | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
| US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| EP2267113B1 (en) | 1997-05-28 | 2013-07-17 | Novartis AG | Culture medium for Neisseria meningitidis with soy bean extract as amino acid source and no protein complexes of animal origin |
| JP4055248B2 (ja) * | 1998-05-25 | 2008-03-05 | 味の素株式会社 | 精製ヒトアクチビン及びその製造方法 |
| GB9902000D0 (en) * | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US6558926B1 (en) | 1999-07-16 | 2003-05-06 | Massachusetts Institute Of Technology | Method for production of tetanus toxin using media substantially free of animal products |
| WO2001036655A2 (en) | 1999-11-12 | 2001-05-25 | Eli Lilly And Company | Method for optimization of a medium for glycopeptide fermentation |
| WO2001036635A2 (en) | 1999-11-15 | 2001-05-25 | Curagen Corporation | Neurite outgrowth-promoting factor homologue and nucleic acids encoding same |
| DE10004024A1 (de) | 2000-01-31 | 2001-08-02 | Guenther Bebenroth | Schaltungsanordnung zum Betreiben von Leuchtdioden |
| US8632785B2 (en) | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| CA2494241C (en) | 2000-02-08 | 2011-06-14 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| CA2398799C (en) | 2000-02-10 | 2009-04-21 | Magna International Inc. | Vehicle tailgate with storage capacity |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| AU2002321012B2 (en) | 2001-08-14 | 2008-07-24 | Statens Serum Institut | A purification process for large scale production of Gc-globulin, product obtained thereby and their use in medicine |
| US7208285B2 (en) | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| US8022172B2 (en) | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
| KR20030060150A (ko) | 2002-01-07 | 2003-07-16 | (주)메디톡스 | 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법 |
| RU2230325C2 (ru) * | 2002-08-15 | 2004-06-10 | Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации | Способ приготовления очищенного препарата ботулинического токсина типа а |
| US7183066B2 (en) | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
| US20040235139A1 (en) | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| CA2472611C (en) * | 2003-07-02 | 2009-09-15 | Filtertek Inc. | Multiple retainer bridge |
| US7160699B2 (en) | 2003-09-25 | 2007-01-09 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
| US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| US7452697B2 (en) | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
| WO2005072433A2 (en) | 2004-01-26 | 2005-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Toxin induced sympathectomy |
| ATE533853T1 (de) | 2004-02-24 | 2011-12-15 | Allergan Inc | Botulinumtoxin-screening-assays |
| BRPI0513850A (pt) | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| US20060069562A1 (en) | 2004-09-10 | 2006-03-30 | Adams Marilyn J | Word categories |
| US7399607B2 (en) | 2004-09-22 | 2008-07-15 | Allergan, Inc. | Fluorescence polarization assays for determining clostridial toxin activity |
| WO2006042149A2 (en) | 2004-10-06 | 2006-04-20 | Allergan, Inc. | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
| US20070277577A1 (en) | 2004-10-29 | 2007-12-06 | Allen Clyde G | Sheet metal brake and hinge mechanism therefor |
| JP2008525381A (ja) * | 2004-12-23 | 2008-07-17 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少 |
| CN1930186A (zh) * | 2005-03-03 | 2007-03-14 | 阿勒根公司 | 为获得梭菌毒素的梭菌细菌培养基及方法 |
| DK1869459T3 (da) | 2005-04-05 | 2010-09-27 | Allergan Inc | Lipofil farve-baserede assays for clostridial-toksin-aktivitet |
| US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| US7744904B1 (en) | 2005-09-26 | 2010-06-29 | B.B. Scientific L.L.C. | Stabilization of Clostridium botulinum neurotoxin complex |
| WO2007059528A2 (en) | 2005-11-17 | 2007-05-24 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
| KR101609894B1 (ko) | 2008-03-14 | 2016-04-08 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| KR20090120222A (ko) | 2008-05-19 | 2009-11-24 | (주)메디톡스 | 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법 |
| JP5826635B2 (ja) | 2009-03-13 | 2015-12-02 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 免疫系調節エンドペプチターゼ活性アッセイ |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP5951490B2 (ja) | 2009-10-21 | 2016-07-13 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
| NL2010545C2 (en) | 2013-03-28 | 2014-09-30 | Ihc Holland Ie Bv | Skidding system for an offshore installation or vessel. |
| KR101339349B1 (ko) | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| US9889608B2 (en) | 2014-11-10 | 2018-02-13 | International Business Machines Corporation | Matching the scale of independent objects or intelligently scaling objects when 3D printing |
| KR101723167B1 (ko) | 2015-04-28 | 2017-04-05 | 주식회사 대웅 | 보툴리눔 독소의 제조를 위한 배지 조성물 |
| KR101775682B1 (ko) | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| KR102463881B1 (ko) | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
-
2009
- 2009-07-13 US US12/502,181 patent/US8129139B2/en active Active
-
2010
- 2010-07-12 CN CN201080038953.7A patent/CN102482332B/zh active Active
- 2010-07-12 PL PL17180720T patent/PL3252070T3/pl unknown
- 2010-07-12 CN CN201610487340.0A patent/CN106117325B/zh active Active
- 2010-07-12 HU HUE10733117A patent/HUE033888T2/en unknown
- 2010-07-12 DK DK10733117.5T patent/DK2454275T3/en active
- 2010-07-12 KR KR1020177003936A patent/KR101916139B1/ko active Active
- 2010-07-12 EP EP17180720.9A patent/EP3252070B1/en active Active
- 2010-07-12 BR BR112012000784-0A patent/BR112012000784A2/pt not_active Application Discontinuation
- 2010-07-12 EP EP22185200.7A patent/EP4141024A1/en not_active Withdrawn
- 2010-07-12 WO PCT/US2010/041745 patent/WO2011008713A1/en not_active Ceased
- 2010-07-12 MX MX2012000615A patent/MX2012000615A/es active IP Right Grant
- 2010-07-12 EP EP19200775.5A patent/EP3640259A1/en not_active Withdrawn
- 2010-07-12 PT PT107331175T patent/PT2454275T/pt unknown
- 2010-07-12 DK DK17180720.9T patent/DK3252070T3/da active
- 2010-07-12 JP JP2012520707A patent/JP5887268B2/ja active Active
- 2010-07-12 CA CA2767760A patent/CA2767760C/en active Active
- 2010-07-12 KR KR1020157018698A patent/KR101667174B1/ko active Active
- 2010-07-12 MX MX2014008854A patent/MX340718B/es unknown
- 2010-07-12 MX MX2016009206A patent/MX375629B/es unknown
- 2010-07-12 KR KR1020187031605A patent/KR20180122039A/ko not_active Ceased
- 2010-07-12 SI SI201031966T patent/SI3252070T1/sl unknown
- 2010-07-12 ES ES10733117.5T patent/ES2643554T3/es active Active
- 2010-07-12 ES ES17180720T patent/ES2770031T3/es active Active
- 2010-07-12 EP EP23194794.6A patent/EP4299070A3/en active Pending
- 2010-07-12 PT PT171807209T patent/PT3252070T/pt unknown
- 2010-07-12 KR KR1020197027795A patent/KR102344985B1/ko active Active
- 2010-07-12 IN IN456DEN2012 patent/IN2012DN00456A/en unknown
- 2010-07-12 KR KR1020127003603A patent/KR101784532B1/ko active Active
- 2010-07-12 PL PL10733117T patent/PL2454275T3/pl unknown
- 2010-07-12 HU HUE17180720A patent/HUE047362T2/hu unknown
- 2010-07-12 EP EP10733117.5A patent/EP2454275B1/en active Active
- 2010-07-12 SI SI201031560T patent/SI2454275T1/sl unknown
- 2010-07-12 RU RU2012104778/10A patent/RU2561459C2/ru active
-
2012
- 2012-01-05 US US13/344,420 patent/US8357541B2/en active Active
- 2012-01-05 US US13/344,399 patent/US8927229B2/en active Active
- 2012-01-12 MX MX2020009978A patent/MX2020009978A/es unknown
- 2012-02-28 US US13/407,662 patent/US8932827B2/en active Active
- 2012-05-10 US US13/468,889 patent/US8324349B2/en active Active
-
2014
- 2014-12-05 US US14/561,402 patent/US9206409B2/en active Active
-
2015
- 2015-10-30 JP JP2015214835A patent/JP6356651B2/ja active Active
- 2015-12-07 US US14/961,327 patent/US9719076B2/en active Active
-
2016
- 2016-11-10 JP JP2016219708A patent/JP6704329B2/ja active Active
-
2017
- 2017-07-31 US US15/664,456 patent/US10465178B2/en active Active
- 2017-10-11 CY CY20171101055T patent/CY1119519T1/el unknown
-
2019
- 2019-11-04 US US16/673,444 patent/US11124786B2/en active Active
- 2019-12-31 CY CY20191101367T patent/CY1122567T1/el unknown
-
2020
- 2020-01-09 JP JP2020001854A patent/JP2020078306A/ja not_active Withdrawn
-
2021
- 2021-06-07 US US17/340,720 patent/US11203748B2/en active Active
- 2021-09-01 JP JP2021142559A patent/JP2021193103A/ja active Pending
- 2021-10-19 US US17/505,537 patent/US11326155B2/en active Active
-
2022
- 2022-01-19 US US17/579,208 patent/US11525130B2/en active Active
- 2022-03-15 US US17/694,962 patent/US20220204958A1/en not_active Abandoned
- 2022-03-15 US US17/694,932 patent/US11518986B2/en active Active
- 2022-04-29 US US17/732,951 patent/US20220251532A1/en not_active Abandoned
- 2022-06-08 US US17/835,503 patent/US11530400B2/en active Active
- 2022-09-27 US US17/953,789 patent/US20230021648A1/en not_active Abandoned
- 2022-09-27 US US17/953,882 patent/US12241098B2/en active Active
- 2022-12-19 US US18/084,505 patent/US20230123158A1/en not_active Abandoned
-
2024
- 2024-06-19 JP JP2024098461A patent/JP2024111147A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00456A (enExample) | ||
| McCarthy et al. | Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins | |
| PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| MX2017007641A (es) | Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas. | |
| MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| MX2009013194A (es) | Proteinas de fusion del receptor para productos finales de glicacion avanzada. | |
| WO2011140135A3 (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases | |
| MX365496B (es) | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| WO2012009289A3 (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases | |
| AU2016264323A8 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| MY186712A (en) | Methods and compositions for inhibiting the interaction of menin with mll proteinss | |
| PH12012502215A1 (en) | Anti-fgfr2 antibodies | |
| UA109278C2 (uk) | Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань | |
| MX387280B (es) | Sistema para la producción dirigida de una proteína terapéutica dentro de una célula objetivo y uso del sistema. | |
| WO2011140132A3 (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases | |
| WO2011139986A3 (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases | |
| WO2011143482A3 (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases | |
| WO2012021249A3 (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases | |
| NO20090305L (no) | Cyklosporin formuleringer | |
| EP2596122A4 (en) | MODULATORS OF SIRT5 AND TESTS FOR SCREENING | |
| EP4302783A3 (en) | Modified relaxin polypeptides and their uses | |
| WO2014145123A3 (en) | Peptide array quality control | |
| MX377781B (es) | Composiciones y metodos para diagnostico y tratamiento del cancer. |